APOB and metabolic syndrome: In addition, the degree of LDL-C and ApoB lowering achieved with both compounds was less than that observed with evinacumab in patients with severe hypertriglyceridemia or mixed dyslipidemia despite dramatic reductions in circulating ANGPTL3 levels3,5,34.